Cargando…
Remote evaluation of STH program coverage: Experiences from the DeWorm3 study, India
BACKGROUND: The DeWorm3 trial is a multi-country study testing the feasibility of interrupting transmission of soil-transmitted helminths by community-wide mass drug administration (cMDA). Treatment coverage during cMDA delivery was validated by in-person coverage evaluation surveys (CES) after each...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653432/ https://www.ncbi.nlm.nih.gov/pubmed/37971962 http://dx.doi.org/10.1371/journal.pntd.0011748 |
_version_ | 1785147775990628352 |
---|---|
author | Aruldas, Kumudha Ramesh, Rohan Michael Oswald, William E. Janagaraj, Venkateshprabhu Titus, Angelin Johnson, Jabaselvi Saxena, Malvika Israel, Gideon John Halliday, Katherine Walson, Judd L. Means, Arianna Rubin Ajjampur, Sitara Swarna Rao |
author_facet | Aruldas, Kumudha Ramesh, Rohan Michael Oswald, William E. Janagaraj, Venkateshprabhu Titus, Angelin Johnson, Jabaselvi Saxena, Malvika Israel, Gideon John Halliday, Katherine Walson, Judd L. Means, Arianna Rubin Ajjampur, Sitara Swarna Rao |
author_sort | Aruldas, Kumudha |
collection | PubMed |
description | BACKGROUND: The DeWorm3 trial is a multi-country study testing the feasibility of interrupting transmission of soil-transmitted helminths by community-wide mass drug administration (cMDA). Treatment coverage during cMDA delivery was validated by in-person coverage evaluation surveys (CES) after each round of treatment. A mobile phone-based CES was carried out in India when access to households was restricted during the COVID-19 lockdown. METHODS: Two focus group discussions were conducted with the survey implementers to document their experiences of conducting phone-based CES via mobile-phone voice calls. PRINCIPAL FINDINGS: In the phone-based CES, only 56% of sampled households were reached compared to 89% during the in-person CES (89%). This was due to phone numbers being wrongly recorded, or calls being unanswered leading to a higher number of households that had to be sampled in order to achieve the sample size of 2,000 households in phone-based CES compared in-person CES (3,600 and 2,352 respectively). Although the phone-based CES took less time to complete than in person coverage evaluations, the surveyors highlighted the lack of gender representation among phone survey participants as it was mostly men who answered calls and were then interviewed. The surveyors also mentioned that eliciting responses to open-ended questions and confirming treatment compliance from every member of the household was challenging during phone based CES. These observations were confirmed by analysing the survey participation data which showed women’s participation in CES was significantly lower in phone-based CES (66%) compared to in-person CES (94%) (Z = -22.38; p<0.01) and that a significantly higher proportion of households provided proxy responses in phone-based CES (51%) compared to in-person CES (21%) (Z = 20.23; p<0.01). CONCLUSIONS: The phone-based CES may be a viable option to evaluate treatment coverage but issues such as participation bias, gender inclusion, and quality of responses will need to be addressed to optimize this methodology. |
format | Online Article Text |
id | pubmed-10653432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-106534322023-11-16 Remote evaluation of STH program coverage: Experiences from the DeWorm3 study, India Aruldas, Kumudha Ramesh, Rohan Michael Oswald, William E. Janagaraj, Venkateshprabhu Titus, Angelin Johnson, Jabaselvi Saxena, Malvika Israel, Gideon John Halliday, Katherine Walson, Judd L. Means, Arianna Rubin Ajjampur, Sitara Swarna Rao PLoS Negl Trop Dis Research Article BACKGROUND: The DeWorm3 trial is a multi-country study testing the feasibility of interrupting transmission of soil-transmitted helminths by community-wide mass drug administration (cMDA). Treatment coverage during cMDA delivery was validated by in-person coverage evaluation surveys (CES) after each round of treatment. A mobile phone-based CES was carried out in India when access to households was restricted during the COVID-19 lockdown. METHODS: Two focus group discussions were conducted with the survey implementers to document their experiences of conducting phone-based CES via mobile-phone voice calls. PRINCIPAL FINDINGS: In the phone-based CES, only 56% of sampled households were reached compared to 89% during the in-person CES (89%). This was due to phone numbers being wrongly recorded, or calls being unanswered leading to a higher number of households that had to be sampled in order to achieve the sample size of 2,000 households in phone-based CES compared in-person CES (3,600 and 2,352 respectively). Although the phone-based CES took less time to complete than in person coverage evaluations, the surveyors highlighted the lack of gender representation among phone survey participants as it was mostly men who answered calls and were then interviewed. The surveyors also mentioned that eliciting responses to open-ended questions and confirming treatment compliance from every member of the household was challenging during phone based CES. These observations were confirmed by analysing the survey participation data which showed women’s participation in CES was significantly lower in phone-based CES (66%) compared to in-person CES (94%) (Z = -22.38; p<0.01) and that a significantly higher proportion of households provided proxy responses in phone-based CES (51%) compared to in-person CES (21%) (Z = 20.23; p<0.01). CONCLUSIONS: The phone-based CES may be a viable option to evaluate treatment coverage but issues such as participation bias, gender inclusion, and quality of responses will need to be addressed to optimize this methodology. Public Library of Science 2023-11-16 /pmc/articles/PMC10653432/ /pubmed/37971962 http://dx.doi.org/10.1371/journal.pntd.0011748 Text en © 2023 Aruldas et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Aruldas, Kumudha Ramesh, Rohan Michael Oswald, William E. Janagaraj, Venkateshprabhu Titus, Angelin Johnson, Jabaselvi Saxena, Malvika Israel, Gideon John Halliday, Katherine Walson, Judd L. Means, Arianna Rubin Ajjampur, Sitara Swarna Rao Remote evaluation of STH program coverage: Experiences from the DeWorm3 study, India |
title | Remote evaluation of STH program coverage: Experiences from the DeWorm3 study, India |
title_full | Remote evaluation of STH program coverage: Experiences from the DeWorm3 study, India |
title_fullStr | Remote evaluation of STH program coverage: Experiences from the DeWorm3 study, India |
title_full_unstemmed | Remote evaluation of STH program coverage: Experiences from the DeWorm3 study, India |
title_short | Remote evaluation of STH program coverage: Experiences from the DeWorm3 study, India |
title_sort | remote evaluation of sth program coverage: experiences from the deworm3 study, india |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653432/ https://www.ncbi.nlm.nih.gov/pubmed/37971962 http://dx.doi.org/10.1371/journal.pntd.0011748 |
work_keys_str_mv | AT aruldaskumudha remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT rameshrohanmichael remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT oswaldwilliame remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT janagarajvenkateshprabhu remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT titusangelin remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT johnsonjabaselvi remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT saxenamalvika remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT israelgideonjohn remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT hallidaykatherine remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT walsonjuddl remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT meansariannarubin remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia AT ajjampursitaraswarnarao remoteevaluationofsthprogramcoverageexperiencesfromthedeworm3studyindia |